Rhabdomyosarcoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.
|
31383960 |
2020 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that ALK is a bona fide immunotherapeutic target and provide a rationale for clinical development of an ALK-ADC approach for neuroblastomas and other ALK-expressing childhood cancers such as rhabdomyosarcomas.
|
30867324 |
2019 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We identified novel ALK fusions in a neuroblastoma (BEND5-ALK) and an astrocytoma (PPP1CB-ALK), novel BRAF fusions in an astrocytoma (BCAS1-BRAF) and a ganglioglioma (TMEM106B-BRAF), and a novel PAX3-GLI2 fusion in a rhabdomyosarcoma.
|
28069802 |
2017 |
Rhabdomyosarcoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Over the last few years, studies have demonstrated the occurrence of autophagy in different Anaplastic Lymphoma Kinase (ALK)-associated cancers, notably ALK-positive anaplastic large cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC), Neuroblastoma (NB), and Rhabdomyosarcoma (RMS).
|
29186933 |
2017 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition to neuroblastoma, the high-grade amplification of ALK has been described in a subset of rhabdomyosarcoma cases.
|
28756644 |
2017 |
Rhabdomyosarcoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that LDK378 reduces cell viability and induces cell death in RMS cell lines at low micromolar IC50 concentrations irrespective of ALK expression levels or phosphorylation status.
|
29045271 |
2017 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To determine the in vitro and in vivo effects and mechanism of action of the second-generation ALK inhibitor ceritinib on RMS cell growth.
|
29067644 |
2017 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, our data suggest a potential role of ALK in pediatric RMS.
|
27385213 |
2016 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase may also have an oncogenic role in rhabdomyosarcomas and peripheral neuroblastic tumors, and they may possibly be treated with ALK inhibitors.
|
26005112 |
2015 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In vitro treatment with crizotinib inhibited ALK and MET proteins, as well as Insulin-like Growth Factor 1 Receptor (IGF1R), with a concomitant robust dephosphorylation of AKT and ERK, two downstream kinases involved in RMS cell proliferation and survival.
|
26445453 |
2015 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Molecular analyses have identified RAS/NF1, hedgehog, IL-4R, and ALK pathway abnormalities as potential therapeutic targets in RMS.
|
24326270 |
2014 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ALK-positive group showed inferior overall survival (OS) compared with ALK-negative group (p=0.014) for both alveolar and embryonal RMS patients.
|
23922356 |
2014 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although it remains controversial whether ALK expression without gene rearrangement is therapeutically relevant, this comprehensive analysis may help future studies on the utility of ALK-targeted therapy for patients with rhabdomyosarcoma.
|
23307059 |
2013 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We also identified possible application of an ALK inhibitor to RMS, as ALK amplification and frequent expression of ALK were detected in our RMS cohort.
|
23578105 |
2013 |
Rhabdomyosarcoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Quantitative assessment of ALK mRNA expression helps to improve risk stratification of RMS patients and identifies tumours with adverse biological characteristics and aggressive behaviour.
|
24149177 |
2013 |
Rhabdomyosarcoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
|
22184391 |
2012 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Future research should aim at the oncogenic role of ALK and the potential effect of ALK inhibitors in RMS.
|
22184391 |
2012 |
Rhabdomyosarcoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase staining was positive in 16 of 30 ARMS (53%) and 9 of 39 nonalveolar RMS (23%) cases (P < 0.05).
|
18788887 |
2009 |
Rhabdomyosarcoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|